A more precise (and patent-protected) variation on CRISPR — and the foundation of Beam's whole pipeline.
↓ scroll to read
✦ The bottom line
Beam was co-founded by David Liu of the Broad Institute — the scientist who invented base editing. The moat isn't a single drug; it's the platform technology (patent portfolio, manufacturing know-how, clinical experience) underneath every program.
↓ the brief below
✦ Teach me
Base editing vs traditional CRISPR
Traditional CRISPR (the technology behind the first approved gene-editing drug, Casgevy) cuts both strands of DNA and lets the cell repair the break — which can introduce errors. Base editing doesn't cut. It chemically converts one DNA letter into another (for example, A to G) at a single, specific site. The promise: more precision, fewer off-target effects, and the ability to fix point mutations directly — the kind that cause sickle cell, AATD, PKU, and many other genetic diseases.
Wall Street calls this
Precision genetic medicine
If base editing turns out to be safer and more controllable than CRISPR, every gene-editing company that *only* has CRISPR is behind. The first FDA approval will set the field's tone.
The platform · multiple shots on goal
5+
programs
Beam runs five active programs from the same base-editing toolkit — sickle cell, AATD, PKU, GSDIa, and antibody-based conditioning. If the platform works, the next program is cheaper to build.
Source · 10-K · Item 1 — Business overview (programs) · FY2025 · Filed Feb 24, 2026
The platform built itself in three steps — academic discovery, commercial pickup, and now clinical readout.
How base editing got from lab bench to clinic
2016
David Liu's lab at Broad Institute publishes the first base editor in Nature.
2017-20
Beam founded; IPO November 2020 at the height of biotech euphoria.
BEAM-302 delivers proof-of-concept data in AATD — base editing works in vivo, not just ex vivo.
Now
BLA for risto-cel targeted by year-end 2026 — would be first base-editing drug ever approved.
Management on the platform's reach
With BEAM-304 in PKU, we are extending the reach of our clinically validated base editing platform to directly correct disease-causing mutations in a new indication, further demonstrating the breadth of what precision genetic medicine can achieve.
↳ The pitch is platform, not pill. If base editing keeps working in new indications, the value goes up multiplicatively — but if it fails in one, doubts spread across all the programs.
Source · 8-K · Item 2.02 — CEO commentary · Q1 2026 · Filed May 7, 2026
⚠
Watch
A real platform with the right founder — but the moat is unproven until the first drug ships.